Immunicum has announced continued compelling survival data from its phase I/II-study in metastatic renal cell carcinoma.
The data showed a median survival for patients with poor prognosis (five patients) currently at 13 months compared to the expected median survival of 8-9 months for patients treated with tyrosine kinase inhibitors. One patient was excluded from the survival study since the patient in question in retrospect did not show any renal cell carcinoma metastases. Of the 11 remaining study patients with verified metastatic renal cancer, eight patients are still alive.
Immunicum has also announced that two patients, whose tumor metastases after INTUVAX-therapy progressed, received add-on therapy with tyrosine kinase inhibitors and subsequently showed remarkable regression of all remaining metastases. In one case, a patient had four brain metastases of which two have gone into complete remission and the remaining two into a continued extensive partial regression. The second case involves a patient with extensive sarcomatoid tumor development, which also showed a partial regression of all metastases. According to the current established knowledge neither of these two patients should have responded to treatment with tyrosine kinase inhibitors.
Immunicum has now submitted an application to the local ethical review board in Uppsala to collect additional data on tumor response from the recently completed phase I/II-study in metastatic renal cell carcinoma.